医学
支气管扩张
内科学
优势比
生活质量(医疗保健)
非结核分枝杆菌
队列
置信区间
前瞻性队列研究
队列研究
逻辑回归
物理疗法
肺
病理
肺结核
分枝杆菌
护理部
作者
Nakwon Kwak,Emily Henkle,Hyeontaek Hwang,Doosoo Jeon,Byung Woo Jhun,Kyung‐Wook Jo,Young Ae Kang,Hyung‐Jun Kim,Joong‐Yub Kim,Young Ran Kim,Yong Soo Kwon,Jae Ho Lee,Jeongha Mok,Youngmok Park,Tae Sun Shim,Hojoon Sohn,Jake Whang,Jae‐Joon Yim
摘要
Abstract Background Improving health-related quality of life (HRQOL) has emerged as a priority in the management of nontuberculous mycobacterial pulmonary disease (NTM-PD). We aimed to evaluate HRQOL and its changes after 6 months’ treatment in patients with NTM-PD. Methods The NTM-KOREA is a nationwide prospective cohort enrolling patients initiating treatment for NTM-PD in 8 institutions across South Korea. We conducted the Quality of Life–Bronchiectasis (QOL-B) at 6-month intervals and evaluated baseline scores (higher scores indicate better quality of life) and changes after 6 months’ treatment. Multivariate logistic regression was performed to identify factors associated with improvement in the QOL-B physical functioning and respiratory symptoms domains. Results Between February 2022 and August 2023, 411 patients were included in the analysis. Baseline scores (95% confidence interval [CI]) for physical functioning and respiratory symptoms were 66.7 (46.7–86.7) and 81.5 (70.4–92.6), respectively. Among 228 patients who completed the QOL-B after 6 months’ treatment, improvements in physical functioning and respiratory symptoms were observed in 61 (26.8%) and 71 (31.1%) patients, respectively. A lower score (adjusted odds ratio; 95% CI) for physical functioning (0.93; 0.91–0.96) and respiratory symptoms (0.92; 0.89–0.95) at treatment initiation was associated with a greater likelihood of physical functioning and respiratory symptom improvement, respectively; achieving culture conversion was not associated with improvement in physical functioning (0.62; 0.28–1.39) or respiratory symptoms (1.30; 0.62–2.74). Conclusions After 6 months of antibiotic treatment for NTM-PD, HRQOL improved in almost one-third, especially in patients with severe initial symptoms, regardless of culture conversion. Clinical Trials Registration ClinicalTrials.gov identifier: NCT03934034.
科研通智能强力驱动
Strongly Powered by AbleSci AI